Pfizer : 2022 ESG Report

Pfizer 2022

Environmental, Social & Governance Report

In This Report

1. Introduction
2. A Letter from our Chairman & CEO

1. A Letter from Our Lead Independent Director
2. 2022 Progress and Highlights
3. Our Approach to ESG

10 Priority ESG Issues

1. Impact Stories
2. Tackling the Health Equity Gap Together

18 Keeping Patients at the Center of Everything We Do

1. Environment
2. Climate Change

24 Sustainable Medicines

1. Social
2. Innovation and Global Health

33 Human Capital

1. Governance
2. Ethics, Transparency, and Quality

46 Accountability

1. Performance
2. Environment

52 Social

58 Governance

1. Appendix
2. GRI Index

71 SASB Index

74 TCFD

1. About This Report
2. Independent Accountants' Report

2 Pfizer 2022 ESG Report

What this report covers

This report shares an overview of our Environmental, Social, and Governance (ESG) vision, achievements, and progress in the year from January 1, 2022 to December 31, 2022, including data on 32 key performance indicators (KPIs), as well as our path toward a sustainable life sciences future.

For more information, please see About this Report on page 81.

Where to find more information

2022 Annual Documents-2022 Annual Review-2022 Annual Report on Form10-K-2023 Proxy Statement

Introduction

Impact Stories

Environment

Social

Governance

Performance

Appendix

Introduction

This report provides a comprehensive overview of Pfizer's commitment to our priority ESG goals toward contributing to long term value creation and a sustainable, responsible, and patient centric business model. Our focus is rooted in our purpose to deliver Breakthroughs that change patients' lives through ethical decision-making and our core values-Courage, Excellence, Equity, and Joy.

Introduction

Impact Stories

Environment

Social

Governance

Performance

Appendix

Letter from our Chairman & CEO

Stepping Up to Meet the Demands of a

Changing World

At Pfizer, our purpose-Breakthroughs that change patients' lives-drivesus to be a force for good in the world. We believe that scientific innovation can help people live longer, healthier lives, and we are proud to continue to advance our scientific pipeline and strengthen our research and development in support of this goal. Specifically, to help ensure science will win against ongoing and future health threats, we invested approximately $11.4 billion in internal research and development programs in 2022.

While many people know about what Pfizer does, fewer know how we go about this work in a way that fulfills our

purpose, builds trust, and takes accountability for the impact we make on society. We take our work seriously, as the impact is felt by not only the more than 1.3 billion patients treated with our medicines and vaccines in 20221, but also the communities in which we, and our stakeholders, live and work.

2022-like the two years preceding it-was punctuated by a growing number of daunting global challenges-fromCOVID-19, which remains a threat to global health, to political and economic instability, to the armed conflict in Ukraine, to increased attacks on marginalized groups that have made it harder for people to live safe, healthy, and productive lives. At the same time, continued climate change has led to observable effects-from floods and heat waves to droughts and dwindling ice caps-and may be linked to not-so-obvious effects, such as potential increased health risks from air pollution, extreme weather events, and pressures on mental health.

Global action and collaboration are needed to address these issues, and as a private-sector leader, Pfizer is committed to responding.

At Pfizer, our commitment is anchored to our six ESG priorities: product innovation; equitable access and pricing; product quality and safety; diversity, equity, and inclusion; climate change; and business ethics. Our progress in these areas is detailed in this report, and we look forward to continuing to engage with colleagues and other stakeholders to hear how we can continue to enhance our impact, both within and outside of Pfizer. We also continue

to refine the metrics we use to measure our performance as the voluntary and emerging regulatory frameworks governing ESG reporting evolve at the local, national, regional, and global level.

Acting Ethically

Our approach to helping address the issues facing our planet and its people is rooted in our purpose. And while our breakthroughs can take the form of new medicines and vaccines, they can also shape new ways of working, new ways of helping ensure equitable access to our innovations, and new ways of leveraging our voice.

We're a company that is guided by our values-courage, excellence, equity, and joy. To that end, we deploy an ethical decision-making framework that seeks to guide how we discuss, consider and act to help address global challenges. Values-andethics-baseddecision-making promotes accountability and helps ensure that integrity, quality, safety, and ethics are foundational to all we do.

Actions > Words

These decisions have led to action. For example, we remain committed to working towards equitable and affordable access to the Pfizer-BioNTechCOVID-19 Vaccine and Pfizer's oral therapy for people around the world. Why? Because our vaccines and medicines cannot positively impact patients if those patients do not have access to them.

This commitment to equitable access extends beyond COVID-19. We live in a time when science can increasingly take on the world's most devastating diseases. But there is a gap determining who can access these innovations, and who cannot. To help bridge this gap, we announced in May 2022 that we will provide on a not-for-profit basis all our innovative medicines and vaccines available in the U.S. or the European Union to 1.2 billion people in 45 lower-income countries and will work closely with global health leaders to make improvements in diagnosis, education, infrastructure, storage, and more. The Accord for a Healthier World-which we expanded in January 2023 to include the full portfolio of products for which we have global rights, bringing the total offering from 23 patented medicines and vaccines to around 500 patented and off-patentproducts-aims to greatly reduce the health inequities that exist between many lower-income countries and the rest of the world.

1 Patient counts are estimates based on multiple data sources. See footnotes within the Performance section for more details.

4

Pfizer 2022 ESG Report

Introduction

Introduction

Impact Stories

Environment

Social

Governance

Performance

Appendix

Letter from our Chairman & CEO

- Continued

Action also requires stepping up during times of international crisis. We remain deeply concerned by the human suffering we have witnessed during the ongoing armed conflict in Ukraine, and we are committed to contributing to ongoing humanitarian efforts that support the safety, health, and wellbeing of people affected by this tragic event. We are determined to ensure the safety of our colleagues and their families, and we are equally determined to facilitate continued access to our medicines and vaccines for patients. But we recognize that we are in a position to do even more. That is why, effective March 14, 2022, Pfizer began donating profits of our Russian subsidiary to the Pfizer Foundation2 for direct humanitarian support to the people of Ukraine, in addition to our ongoing humanitarian response efforts in the region. Pfizer, through The Pfizer Foundation, has committed over $30 million to support these efforts.

We believe that product donations play an important role in relief and humanitarian emergencies. We are proud to work through established non-governmental organizations with expertise in managing product donations in connection with humanitarian emergencies. In 2022, this included Hurricane Fiona, Hurricane Ian, the Afghanistan earthquake, and the flooding in Pakistan.

We recognize that planetary health has a profound impact on human health, which is why we are building on more than 20 years of climate action to reduce our company and value chain Greenhouse Gas (GHG) emissions. In June 2022, we announced our aim to achieve the voluntary Net-Zero Standard by 2040, ten years earlier than the timeline described in the standard. As part of this commitment, we aim to reduce our company GHG emissions by 95 percent and our value chain GHG emissions by 90 percent from 2019 levels through accelerating the transition away from fossil fuels and engaging suppliers to catalyze equivalent action.

Force for Good

As we look ahead, as remarkable as 2022 has been for Pfizer, I believe we have only scratched the surface of the transformative impact we can have on human health.

Our third ESG Report, which shares our vision and approach, showcases progress on key strategies and reaffirms our commitment to keeping patients at the center of all we do and to furthering the positive impact that we have on the world.

Nobody can predict with certainty how the world will change in 2023, and what challenges humankind will have to overcome. But I do know this: all of us at Pfizer consider it a privilege to be allowed by society to help address these issues. Against this backdrop, we remain committed to keeping patients as our North Star, applying ethical decision-making frameworks to our work, embedding ESG into our corporate strategies, and continuing to be a force for good in the world.

Dr. Albert Bourla

Pfizer Chairman & Chief Executive Officer

2 The Pfizer Foundation is a separate legal entity from Pfizer Inc. with distinct legal restrictions.

5

Pfizer 2022 ESG Report

Introduction